Pulmocide Ltd is pleased to announce that in vitro data published in the Journal of Antimicrobial Chemotherapy highlight the potential of its novel antifungal candidate PC945 in the treatment of Candida auris.
- C.auris is often multi-drug resistant and new treatment options are urgently required
- PC945 is a first-in-class azole for inhaled delivery and is already in clinical testing for prevention or treatment of invasive lung infections
London, UK, 13 August 2019 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that in vitro data published in the Journal of Antimicrobial Chemotherapy highlight the potential of its novel antifungal candidate PC945 in the treatment of Candida auris.
C.auris is an emerging yeast infection that is expecting to pose a growing and significant health threat owing to its multi-drug resistant nature.
The paper ‘In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris’ (available to view here) outlines the susceptibility of C.auris to Pulmocide’s novel antifungal triazole, PC945, optimized for topical delivery.
PC945, Pulmocide’s lead asset, was found to be a more potent inhibitor than posaconazole, voriconazole and fluconazole of C.auris isolates collected globally, warranting further laboratory and clinical evaluations.
Dr Garth Rapeport, Chief Executive Officer of Pulmocide, said: “We are pleased to report these promising data. Pulmocide is very aware of the growing concern aroundCandida auris and we are delighted to be able to contribute to the growing body of research characterising this newly identified pathogen.
“C.auris has been isolated from all manner of upper and lower respiratory tract samples as well as from the air in hospital settings. Targeting upper or lower airway delivery by aerosolization of antifungals can prevent systemic side effects by achieving high local concentrations at the primary site of infection. PC945 is the first antifungal triazole specifically designed as a once-daily, topical/aerosolized treatment for upper airway fungus colonization. Although the transmission route of C.auris has not been fully identified, these in vitro data of PC945 indicate that it is a promising drug to prevent or treat C.auris infection.”
The full publication is available online and can be viewed here.
- Ends -
